Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q2

9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥11.4bn2023-07-01 → 2023-12-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥11.2bn2022-07-01 → 2022-12-31Cons.Net sales
Operating income¥2.4bn2023-07-01 → 2023-12-31Cons.Operating income
Operating income¥2.2bn2022-07-01 → 2022-12-31Cons.Operating income
Ordinary income¥2.4bn2023-07-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.2bn2022-07-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥2.4bn2023-07-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.2bn2022-07-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss
Net income¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss
Total assets¥29.6bnat 2023-12-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥7.7bnat 2023-12-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.0bnat 2023-12-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥19.6bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥11.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥10.3bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥10.0bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥8.2bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥8.4bnat 2022-06-30dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2023-07-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.7bn2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥518m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥644m2023-07-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥304m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥120m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥639m2023-07-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥812m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥600m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥39.462023-07-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.342023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.192022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio74.2%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.8%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-12-31−¥38m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥7.9bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥7.0bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2023-12-31¥871m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.0bn
—segment totalrevenue2023-07-01 → 2023-12-31¥12.3bn
—segment totalrevenue external2023-07-01 → 2023-12-31¥11.4bn
—segment totalrevenue intersegment2023-07-01 → 2023-12-31¥871m
—segment totalsegment profit2023-07-01 → 2023-12-31¥2.4bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31¥22m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥8.1bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥7.2bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥925m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥761m
—segment totalrevenue2022-07-01 → 2022-12-31¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥11.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥925m
—segment totalsegment profit2022-07-01 → 2022-12-31¥2.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Other comprehensive incomePrior1YTDDuration-66473000JPY
Other comprehensive incomeCurrentYTDDuration-25775000JPY
Comprehensive incomePrior1YTDDuration1327870000JPY
Comprehensive incomeCurrentYTDDuration1537530000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration1327870000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration1537530000JPY
Income before income taxesPrior1YTDDuration2176866000JPY
Income before income taxesCurrentYTDDuration2440109000JPY
Depreciation and amortization ope cfPrior1YTDDuration339027000JPY
Depreciation and amortization ope cfCurrentYTDDuration350895000JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration-12929000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration-13219000JPY
Increase decrease in provision for directors retirement benefits ope cfPrior1YTDDuration6216000JPY
Increase decrease in provision for directors retirement benefits ope cfCurrentYTDDuration6514000JPY
Increase decrease in net defined benefit asset ope cfPrior1YTDDuration7227000JPY
Increase decrease in net defined benefit asset ope cfCurrentYTDDuration8353000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration5493000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration14566000JPY
Loss gain on valuation of investment securities ope cfPrior1YTDDuration3071000JPY
Loss gain on valuation of investment securities ope cfCurrentYTDDuration－JPY
Interest and dividends income ope cfPrior1YTDDuration-1841000JPY
Interest and dividends income ope cfCurrentYTDDuration-1948000JPY
Interest expenses ope cfPrior1YTDDuration3949000JPY
Interest expenses ope cfCurrentYTDDuration3359000JPY
Insurance income ope cfPrior1YTDDuration－JPY
Insurance income ope cfCurrentYTDDuration-26533000JPY
Foreign exchange losses gains ope cfPrior1YTDDuration-416000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration609000JPY
Loss gain on sales and retirement of noncurrent assets ope cfPrior1YTDDuration437000JPY
Loss gain on sales and retirement of noncurrent assets ope cfCurrentYTDDuration0JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration-1411175000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-816827000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-394553000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-48493000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration720564000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration508016000JPY
Decrease increase in accounts receivable other ope cfPrior1YTDDuration-6967000JPY
Decrease increase in accounts receivable other ope cfCurrentYTDDuration1576000JPY
Other net ope cfPrior1YTDDuration-122442000JPY
Other net ope cfCurrentYTDDuration-208767000JPY
Subtotal ope cfPrior1YTDDuration1312525000JPY
Subtotal ope cfCurrentYTDDuration2218212000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration4115000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration1780000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-3661000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-3121000JPY
Proceeds from subsidy ope cfPrior1YTDDuration766000JPY
Proceeds from subsidy ope cfCurrentYTDDuration776000JPY
Proceeds from insurance income ope cfPrior1YTDDuration－JPY
Proceeds from insurance income ope cfCurrentYTDDuration26533000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-07-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass